What MACI is and who it is designed for

MACI — matrix-induced autologous chondrocyte implantation — is designed for patients with a focal, full-thickness cartilage defect in the knee where smaller single-stage procedures are unlikely to provide durable repair but joint replacement remains premature. The typical indication is an ICRS grade 3 or 4 lesion measuring roughly 2–10 cm², in a skeletally mature patient with good mechanical alignment and no sign of diffuse osteoarthritis elsewhere in the joint.

The procedure takes place in two separate stages. At the first, a small biopsy of healthy cartilage is taken arthroscopically; the harvested chondrocytes are then cultured in a laboratory over several weeks. At the second stage, those cells — now seeded onto a Type I/III collagen membrane — are implanted directly into the prepared defect. This membrane-based approach removes the need for a periosteal flap, one of the principal technical limitations of first-generation ACI.

MACI is not appropriate where cartilage loss is widespread or advanced: in those cases, joint preservation surgery is unlikely to be sufficient and a replacement discussion becomes more relevant. For the right patient, though, the central aim is to restore a durable cartilage surface and delay — or avoid entirely — the need for a knee replacement. The sections that follow cover what recovery involves, when return to sport becomes realistic, and what the long-term evidence shows.

How MACI recovery unfolds phase by phase

Phase 1: protecting the graft (weeks 1–12)

The first three months are the most medically constrained period of the recovery. The newly implanted graft needs time to adhere, vascularise, and begin integrating with the underlying bone — a biological process that cannot be safely shortened. Mechanical overloading in these early weeks risks displacement before that anchoring is secure, which is why the initial restrictions carry genuine clinical weight.

Crutches are standard for the first few weeks, and a hinged knee brace limits uncontrolled movement. Where the graft sits in the joint changes the weight-bearing rules considerably. For patellofemoral lesions, patients typically bear full weight from the outset — though the brace is kept locked in extension. For tibiofemoral lesions and those on the femoral condyle, full weight-bearing is generally deferred until around 7–9 weeks, once the graft has had sufficient time to consolidate. Generic protocols can misapply this distinction, so confirming lesion location with the surgical team early is worthwhile.

Range-of-motion exercises begin promptly despite the loading restrictions. A target of 90° flexion is typical by around week four; most patients achieve full range of motion by 8–12 weeks, at which point brace discontinuation usually follows.

Practically, the early phase is less isolating than it may appear. Seated desk work is typically possible within two weeks of surgery, and comfortable, unaided walking is realistic for most patients by the end of month three.

Phase 2: rebuilding strength (months 3–6)

Once the graft is sufficiently consolidated, attention shifts to rebuilding the quadriceps and the wider lower-limb musculature. Physiotherapy intensity increases during this phase, with progressive resistance exercises introduced alongside balance and proprioception work.

Driving and stationary cycling become possible for most patients during this period — both useful for maintaining fitness whilst still protecting the repair. By the end of month six, lower-limb strength is substantially restored, though the graft continues maturing biologically into Phase 3.

Returning to sport after MACI

Around 82% of patients who undergo ACI or MACI return to sport, according to a 2023 IJSPT review — a strong headline figure, though it also means roughly one in five do not fully regain their previous level of participation. Across all knee cartilage repair procedures, pooled return-to-sport rates range from 75% to 89% (2020 systematic review), placing MACI solidly within that range.

Mean time to return stands at 11.8 ± 3.8 months — longer than osteochondral allograft (9.6 months), which reflects the two-stage, graft-maturation biology rather than any deficiency in the procedure itself. For high-impact or pivoting sports such as football, basketball, and skiing, full reintegration is typically deferred to 12–18 months, while the collagen membrane completes its biological conversion into functional repair tissue.

What has changed in recent years is how readiness is determined. Modern rehabilitation has moved away from fixed calendar milestones towards criteria-based testing: objective measures of quadriceps strength, single-leg hop performance, and sport-specific movement quality that must all be met before clearance is given. This shifts the benchmark to what the patient can demonstrably do, rather than how long they have waited.

Blood flow restriction (BFR) training has become a useful tool within this framework. Applied during the early protected phase, it allows patients to maintain quadriceps mass and neuromuscular activation under low mechanical load — staying ahead of deconditioning without stressing an immature graft. Younger patients with smaller, isolated defects consistently achieve the upper end of the outcome range; in subgroups such as those with patellofemoral lesions, the published evidence is thinner, which makes the criteria-based assessment process — rather than any population average — the more meaningful guide to individual prognosis.

What 10-year data says about MACI durability

The most comprehensive long-term data comes from a 2024 systematic review of 168 patients followed for a minimum of ten years. The headline findings are encouraging: patient-reported outcomes improve significantly after MACI and those gains hold over the follow-up period, the all-cause reoperation rate sits at 9.0%, and progression to total knee arthroplasty affects 7.4% of patients at 10–17 years. For a joint-preserving procedure aimed at delaying or avoiding replacement, that conversion rate is a meaningful benchmark. SUMMIT trial data reinforce the procedure's positioning further: for defects of 3 cm² or larger, MACI outperforms microfracture on KOOS pain and function scores at both two and five years — supporting its role as the preferred option for bigger lesions where microfracture is unlikely to provide durable repair.

The picture is not uniformly reassuring, however, and patients often arrive having read that MACI 'regrows cartilage' — a framing that deserves honest qualification. Biopsy analysis shows that 73% of grafts produce fibrocartilage rather than true hyaline cartilage, and 80% are measurably softer than the surrounding native tissue. Functional improvement clearly occurs despite this tissue-quality limitation, but it is worth noting that the graft is not a like-for-like cartilage replacement.

MRI data add a further nuance over time. Graft fill, which reaches approximately 90% at two years, falls to 72% at five years and 49% at ten years — and outcome scores that plateau through year five begin declining by year ten. This is not a reason to avoid MACI, but it does argue for structured long-term monitoring rather than treating a good five-year result as the end of the story.

The most specific signal warranting that ongoing surveillance comes from intralesional bony overgrowth, which occurs in 44% of patients by 60 months. It does not visibly alter clinical scores at that point, but it is associated with altered biophysical properties in the opposing cartilage — a finding that points towards cumulative joint stress building quietly beneath the surface.

Factors that shape your individual MACI outcome

Several variables consistently shift where an individual lands within the published outcome ranges — understanding them is useful when discussing MACI with a surgeon pre-operatively.

Age. Younger patients, particularly those below 50, achieve the highest functional scores and return-to-sport rates. The evidence base for MACI is most robust in this group; outcomes in older patients are less well characterised in the literature.

Defect size and location. Smaller, isolated lesions on the femoral condyle yield more predictable results than larger, patellofemoral, or multi-compartment defects. Patellofemoral lesions also carry a distinct weight-bearing protocol and a somewhat thinner evidence base for return-to-sport rates specifically.

BMI. A higher body mass index prolongs the protected phase and is associated with lower functional scores at follow-up. Most surgical teams discuss a target BMI range before confirming the procedure.

Prior marrow stimulation. Microfracture leaves subchondral bone changes that can compromise graft integration — one of the stronger pre-surgical considerations, and worth raising explicitly if there is a previous procedure in the history.

Concomitant procedures. Alignment correction (HTO or DFO osteotomy) or ligament reconstruction performed alongside MACI extends the overall recovery window, but addressing the mechanical environment may improve long-term graft survival by reducing abnormal load on the repair tissue.

Of all these factors, adherence to the phased rehabilitation programme is the one most directly within a patient's control after surgery. Progressive loading milestones, quadriceps strengthening targets, and criteria-based sport clearance all depend on consistent engagement — a point worth clarifying at any pre-operative consultation alongside the structural variables above.

1. [1] Comparison of MACI vs AMIC and Arthroscopic Minced Cartilage – 2-Year Follow-Up on Patient-Reported Pain and Functional Outcomes. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194
2. [2] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
3. [3] Consensus on Rehabilitation Guidelines among Orthopedic Surgeons following MACI for Knee Cartilage Lesions. (2020). https://doi.org/10.1177/1947603520968876 https://doi.org/10.1177/1947603520968876
4. [4] A Prospective Outcome, MRI and Biopsy Study of MACI Cartilage Transplantation. (2017). https://doi.org/10.1177/2325967117S00186 https://doi.org/10.1177/2325967117S00186
5. [5] Bone Marrow Edema-Like Signal After Cartilage Repair Does Not Affect Outcomes in a Five-Year Follow-Up. (2024). https://doi.org/10.1007/s00330-024-11078-8 https://doi.org/10.1007/s00330-024-11078-8
6. [6] Long-Term Impact of Intralesional Bony Overgrowthon Opposing Cartilage Integrity: Five-Year Results Following Cartilage Repair. (2025). https://doi.org/10.1177/19476035251335008 https://doi.org/10.1177/19476035251335008